EsoCap Technology
IP and Data Protection
Several worldwide patents owned by EsoCap have been filed.
EsoCap has filed a first patent application, with patents granted in the USA, Japan, Australia, South Africa, Mexico, Israel, South Korea, New Zealand, Russia, Brazil and Canada and expected in the EU and further strategic countries. Ring-fencing patent applications cover the capsule holder and production methods. Two additional patent applications have been filed regarding the manufacturing process. More recently 3 patent applications have been filed regarding the application of the EsoCap platform in several diseases of the esophagus.
Orphan Drug Designation (ODD)
EsoCap AG has received Orphan Drug Designation (ODD) from the United States Food & Drug Administration (FDA) for use of ESO-101 in the treatment of EoE. The FDA has recognized ESO-101’s potential to offer a significant therapeutic benefit for patients suffering from EoE. Orphan Drug Designation provides a sponsor with certain benefits and incentives, including a period of marketing exclusivity when regulatory approval is obtained for the designated indication. A similar application has been submitted in Europe.
